Initial characterization of MRI-free pipelines across the AD clinical spectrum for tau PET has been promising, withLandau et al. (2023)showing high correspondence ranging from R2= 0.88 to R2= 0.97 in entorhinal and composite temporal regions with cross-sectional [18F]Flortaucipir (FTP) PET data. Here, MAPT is linked to Alzheimer disease.